Globe Life delivered first quarter results that were generally consistent with Wall Street’s expectations, as revenue growth in both life and health insurance segments contributed to stable performance. Management pointed to continued strength in health premium revenue, up 13% year-on-year, and highlighted the company’s ability to generate double-digit growth in net operating income per share in seven of the last eight quarters. CEO Frank Svoboda emphasized the resilience of Globe Life’s business model, noting, “Despite the challenges faced by working class Americans in the current economic environment, Globe Life has produced robust results.”

Is now the time to buy GL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Globe Life’s Q1 Earnings Call

• Francis Matten (BMO Capital Markets): Asked about persistently elevated lapse rates at American Income. CFO Thomas Kalmbach said the higher lapse rates reflect both economic pressure and normal fluctuations, while management views current trends as broadly resilient and within historical norms.

• Wilma Jackson Burdis (Raymond James): Sought clarity on the higher-than-expected share buyback pace. Kalmbach attributed this to slightly stronger excess cash flow and opportunistic repurchases during periods of lower share price in the quarter.

• Wesley Carmichael (Wells Fargo): Inquired about the sustainability of United American’s health sales growth after a strong first quarter. Management acknowledged high comparables in later quarters but maintained a positive outlook given current Medicare supplement tailwinds.

• Andrew Kligerman (TD Cowen): Asked if the favorable assumption updates for life margins are likely to recur in future years. Kalmbach explained that while further updates are possible, the primary driver is continued favorable mortality trends, with future gains expected to moderate.

• Suneet Kamath (Jefferies): Questioned whether macroeconomic pressures are causing incremental stress on Globe Life’s customer base. Management emphasized the resilience of its policyholders, noting that policy affordability and the value placed on coverage have historically limited lapse volatility.

Catalysts in Upcoming Quarters

In future quarters, our analysts will be watching (1) the pace of agent count recovery, particularly at American Income, following compensation changes; (2) the realization of anticipated administrative expense savings as AI initiatives scale; and (3) the effect of Medicare supplement rate increases on health underwriting margins. Progress on these fronts, as well as sustained favorable mortality trends, will be key signposts for execution against Globe Life’s strategic objectives.

Globe Life currently trades at $153.38, up from $151.25 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.